Regeneron Pharmaceuticals, Inc. to Issue Quarterly Dividend of $0.88 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) announced a quarterly dividend on Tuesday, February 4th,RTT News reports. Stockholders of record on Thursday, February 20th will be paid a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%.

Regeneron Pharmaceuticals Trading Up 2.7 %

Shares of Regeneron Pharmaceuticals stock traded up $18.78 during trading on Wednesday, reaching $715.83. 654,785 shares of the company were exchanged, compared to its average volume of 914,689. Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The business has a 50-day moving average price of $718.04 and a 200-day moving average price of $916.32. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $78.66 billion, a price-to-earnings ratio of 17.71, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the business posted $11.86 EPS. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on REGN shares. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.